In vitro pharmacodynamics of vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus: Considering the variability in observed tissue exposure

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 2, 2016, Pages 955-961

  Hamada, Yukihiro ^a,b   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; DIABETIC PATIENT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; BACTERIAL COUNT; DRUG EFFECTS; MICROBIOLOGY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84957927507     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01553-15     Document Type: Article

References (35)

1. Edelsberg J, Taneja C, Zervos M, Haque N, Moore C, Reyes K, Spalding J, Jiang J, Oster G. 2009. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 15:1516-1518. http://dx.doi.org/10.3201/eid1509.081228.
2. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. 2014. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 59:e10-52. http://dx.doi.org/10.1093/cid/ciu296.
3. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666-674. http://dx.doi.org/10.1056/NEJMoa055356.
4. Talan DA, Krishnadasan A, Gorwitz RJ, Fosheim GE, Limbago B, Albrecht V, Moran GJ. 2011. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 53:144-149. http://dx.doi.org/10.1093/cid/cir308.
5. Davis SL, Perri MB, Donabedian SM, Manierski C, Singh A, Vager D, Haque NZ, Speirs K, Muder RR, Robinson-Dunn B, Hayden MK, Zervos MJ. 2007. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 45:1705-1711. http://dx.doi.org/10.1128/JCM.02311-06.
6. Miller LG, Eells SJ, David MZ, Ortiz N, Taylor AR, Kumar N, Cruz D, Boyle-Vavra S, Daum RS. 2015. Staphylococcus aureus skin infection recurrences among household members: an examination of host, behavioral, and pathogen-level predictors. Clin Infect Dis 60:753-763. http://dx.doi.org/10.1093/cid/ciu943.
7. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak JM, Talan DA, Chambers HF, Infectious Diseases Society of America. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18-55. http://dx.doi.org/10.1093/cid/ciq146.
8. Raymakers JT, Houben AJ, van der Heyden JJ, Tordoir JH, Kitslaar PJ, Schaper NC. 2001. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. Diabet Med 18:229-234. http://dx.doi.org/10.1046/j.1464-5491.2001.00460.x.
9. Skhirtladze K, Hutschala D, Fleck T, Thalhammer F, Ehrlich M, Vukovich T, Müller M, Tschernko EM. 2006. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 50:1372-1375. http://dx.doi.org/10.1128/AAC.50.4.1372-1375.2006.
10. Kim A, Suecoff LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP. 2008. In vivo microdialysis study of penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob Agents Chemother 52:3941-3946. http://dx.doi.org/10.1128/AAC.00589-08.
11. Bulik CC, Wiskirchen DE, Shepard A, Sutherland CA, Kuti JL, Nicolau DP. 2010. Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother 54:5209-5213. http://dx.doi.org/10.1128/AAC.01051-10.
12. Wiskirchen DE, Shepard A, Kuti JL, Nicolau DP. 2011. Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemother 55:4170-4175. http://dx.doi.org/10.1128/AAC.00445-11.
13. Payne CJ, Thomson AH, Stearns AT, Watson DG, Zhang T, Kingsmore DB, Byrne DS, Binning AS. 2011. Pharmacokinetics and tissue penetration of vancomycin continuous infusion as prophylaxis for vascular surgery. J Antimicrob Chemother 66:2624-2627. http://dx.doi.org/10.1093/jac/dkr326.
14. Housman ST, Bhalodi AA, Shepard A, Nugent J, Nicolau DP. 2015. Vancomycin tissue pharmacokinetics in patients with lower limb infections via in vivo microdialysis. J Am Podiatr Med Assoc 105:381-388. http://dx.doi.org/10.7547/14-033.
15. Hamada Y, Kuti JL, Nicolau DP. 2015. Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. J Antimicrob Chemother 70:2064-2067. http://dx.doi.org/10.1093/jac/dkv074.
16. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
17. MacVane SH, So W, Nicolau DP, Kuti JL. 2014. In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother 58:7520-7526. http://dx.doi.org/10.1128/AAC.03742-14.
18. Hagihara M, Sutherland C, Nicolau DP. 2013. Development of HPLC methods for the determination of vancomycin in human plasma, mouse serum, and bronchoalveolar lavage fluid. J Chromatogr Sci 51:201-207. http://dx.doi.org/10.1093/chromsci/bms128.
19. Harigaya Y, Bulitta JB, Forrest A, Sakoulas G, Lesse AJ, Mylotte JM, Tsuji BT. 2009. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob Agents Chemother 53:3894-3901. http://dx.doi.org/10.1128/AAC.01585-08.
20. Rybak MJ, Lomaestro B, Rotschafer JC, Moellering R, Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82-98. http://dx.doi.org/10.2146/ajhp080434.
21. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory infections. Clin Pharmacokinet 43:925-942. http://dx.doi.org/10.2165/00003088-200443130-00005.
22. Kullar R, Davis SL, Levine DP, Rybak MJ. 2011. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 52:975-981. http://dx.doi.org/10.1093/cid/cir124.
23. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Warren SJ, Gao W, Howden BP, Johnson PD. 2013. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 57:1654-1663. http://dx.doi.org/10.1128/AAC.01485-12.
24. 24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. Clin Ther 35:772-779. http://dx.doi.org/10.1016/j.clinthera.2013.05.008.
25. Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ. 2015. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother 59:2978-2985. http://dx.doi.org/10.1128/AAC.03970-14.
26. Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP. 2012. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 56:202-207. http://dx.doi.org/10.1128/AAC.05473-11.
27. LaPlante KL, Rybak MJ. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48:4665-4672. http://dx.doi.org/10.1128/AAC.48.12.4665-4672.2004.
28. Larsson JA, Walker KJ, Raddatz JK, Rotschafer JC. 1996. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 38:589-597. http://dx.doi.org/10.1093/jac/38.4.589.
29. Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. 2010. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 51:641-650. http://dx.doi.org/10.1086/655827.
30. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. 2014. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370:2169-2179. http://dx.doi.org/10.1056/NEJMoa1310480.
31. Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, Manos P, Keech R, Singh R, heller B, Bubnova N, O'Riordan W. 2015. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis 60:254-262. http://dx.doi.org/10.1093/cid/ciu778.
32. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. 2013. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Department of Health and Human Services, Washington, DC. http://www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf. Accessed 26 June 2015.
33. Bhalodi AA, Hagihara M, Nicolau DP, Kuti JL. 2014. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. Antimicrob Agents Chemother 58:672-677. http://dx.doi.org/10.1128/AAC.01516-13.
34. Duvanel T, Auckenhaler R, Rohner P, Harms M, Suarat JH. 1989. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med 149:293-296.
35. Kallstrom G. 2014. Are quantitative bacterial wound cultures useful? J Clin Microbiol 52:2753-2756. http://dx.doi.org/10.1128/JCM.00522-14.